{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-104616","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.513540+00:00","generated_at":"2026-06-23T06:22:39.144586+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nasdaq Panel grants Avenue Therapeutics extension to Oct 31 to meet equity requirement, Oct 6 for bid price","bullets":["Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.","Company must also satisfy minimum bid price of $1.00 per share by Oct 6, 2022.","Previously, Company was non-compliant with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).","Hearing request on Aug 16, 2022 stayed suspension until Panel decision on Sep 29."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-104616","json":"https://secwatch.observer/filing/0001104659-22-104616.json","markdown":"https://secwatch.observer/filing/0001104659-22-104616.md","text":"https://secwatch.observer/filing/0001104659-22-104616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/0001104659-22-104616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/tm2227168d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:22:39.144586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}